activity ( Figure 1B) . Absence of these normal regulators of the AP are the cause of a number of human diseases, including atypical hemolytic uremic syndrome (aHUS), [1] [2] [3] [4] [5] [6] C3 glomerulopathies (C3GN), [1] [2] [3] [4] [5] [6] age-related macular degeneration (AMD), [7] [8] [9] [10] [11] and protein-losing enteropathy. 12 Crry is a widely expressed type 1 transmembrane protein in rodents that downregulates the AP. It has strong cofactor activity for C3b and moderate decay accelerating activity for the classical pathway. [13] [14] [15] Crry's broad expression profile and regulatory activities are similar to membrane cofactor protein (MCP/CD46) in primates ( Figure 1B) . 16 MCP has a limited expression profile in rodents, being present primarily on the inner acrosomal membrane of spermatozoa. 9, [16] [17] [18] Crry −/− concepti produced by Crry +/− × Crry +/− matings are attacked by the maternal AP leading to loss before 10 days. 15 Notably, Crry −/− pups can be rescued if the mother is deficient in any 1 of the 4 components (C3, FB, FD, and properdin) of the AP (13) (14) (15) and X. Wu and J.P. Atkinson, unpublished). Fetal loss that occurs is not dependent on antibody (μMT −/− background) or the classical or lectin pathway of complement (C4 −/− background). 13 Moreover, demise is not mediated by the MAC, as the C6-deficient mouse conceptus does not rescue the demise phenotype. 19 However, C5a may play a minor role: C5 −/− background led to ~5% of offspring being Crry −/− although much less than the expected 25% of offspring. 13 These results indicate that fetal loss occurs primarily through APdirected events, prior to formation of the C5 convertase and the membrane attack complex.
Herein, we test the hypothesis that the ability of C3b to engage the AP feedback loop in the absence of proper membrane regulation induces the placental lesion yielding the demise of the Crry −/− mouse. Specifically, we surmise that a reduction in maternal AP activity at ~6.5 days post-coitus (dpc) would prevent conceptus demise. The mouse blastocyst enters the uterus at 4.5 dpc yet the conceptus is not directly exposed to maternal blood until 5.0-6.5 dpc. 20 As early as 6.5 but completely by 7.5 dpc, the ectoplacental cone cells that will evolve into the chorioallantoic placenta are bathed in maternal blood, thereby exposing to proteins of the complement cascade. Neutrophil depletion and C3a receptor blockade failed to rescue the conceptus. Overall, the results further suggest that C3b deposition is responsible for the loss of the conceptus. [13] [14] [15] 19 2 | MATERIAL S AND ME THODS
| Mouse breeding and genotyping
Mice were bred and maintained under pathogen-free conditions at Washington University School of Medicine (WUSM) in St. Louis, MO in accordance with institutional animal care guidelines. The
Crry knockout mouse was originally generated by Molina and colleagues 14 and has been maintained at WUSM. The Crry −/− allele was genotyped by PCR as described. 15 The C3aR knockout mouse was a gift from Richard Wetsel (University of Texas, Houston) and genotyped by PCR.
| Timed matings and harvesting embryos
After female mice were placed in the male's cage, each subsequent day the female was checked for a vaginal plug. 
| Frozen section histology
Implantation sites, harvested as above, were dehydrated in 20% sucrose overnight at 4°C, flash frozen in optimal cutting temperature (Sakura USA, Torrance, CA) with 2-methylbutane, and cooled with dry ice. Cassettes were stored at −80°C. Frozen sections (7 μm)
were prepared on a Leica CryoStat. 
| Immunohistology
Implantation sites were fixed in 10% formalin overnight, embedded in paraffin, 8 μm sections were rehydrated, antigen retrieval was performed, non-specific binding was blocked, and specific immunostaining was conducted as described below. In the case of Crry staining, antigen retrieval was performed in 10 mmol/L citric acid (anhydrous; Sigma-Aldrich), 0.05% Tween-10, pH 6.0 in a pressure cooker for 3 minutes. Blocking and staining were performed in 1% BSA, 10% donkey serum, and 5% mouse serum in PBS. For trophoblast staining, 7.5 dpc implantation sites were collected as described above. Antigen retrieval was accomplished with 10 mmol/L 
| FACS analysis of cells derived from 7.5 dpc implantation sites
Implantation sites were harvested as described above. Each site was cut into 12 pieces and placed in RPMI 5% fetal bovine serum (FBS).
These pieces were digested in RPMI containing 5% FBS, 300 μg/ mL collagenase F (Sigma-Aldrich), 200 μg/mL collagenase L (SigmaAldrich), 500 μg/mL Dispase (Gibco), and 2 U/mL DNase-1 (Roche)
at 37°C for 30-45 minutes with a magnetic stir bar for agitation.
Cells were passed over a 70 μm strainer (BD) to create a single- 
| Cobra venom factor (CVF) treatment
Cobra venom factor (Quidel, A600) was administered intraperitoneally (20 μg/mouse) with a 31G insulin syringe (Terumo). Depletion of C3 occurs in <1 hour. C3 hemolytic and antigenic activity is undetectable for up to 3-4 days and then there is a gradual increase to normal levels over approximately a week.
21,22

| Neutrophil depletion
Neutrophils were depleted by intraperitoneal injection (IP) injection of RB6-8C5, a rat IgG2b mAb against Gr-1 (Ly6G/C). A 250 μg dose of this Ab depleted neutrophils in the periphery for 5 days and a 500 μg dose depleted for 6 days. Both doses are followed by a rebound neutrophilia (approximately a doubling of pre-depletion levels), which we were unable to overcome with an additional IP dose 4 days after the first dose. 1A8 is a second anti-Gr-1 rat IgG2a Ab (BioXCell). A 500 μg dose of 1A8 depleted ~50% of the neutrophils when the peripheral blood was assayed at 72 hours.
In the initial experiments, we used RB6-8C5 that was a gift from Emil Unanue (Washington Univ. School of Medicine, Department of Pathology and Immunology, St. Louis, MO). 23 RB6-8C5 was also produced within the laboratory by hybridoma cells. The mAb was purified from supernatants on a protein G column and then dialyzed against PBS. RB6 was also purchased from BioXCell (West Lebanon, NH).
| RE SULTS
| Timing of AP activity required for conceptus loss and depletion of the AP by CVF
Crry −/− products of conception are known to undergo demise before 10.5 dpc with maternal AP components playing a critical role. [13] [14] [15] 24 We sought to determine when the lethal AP activity occurred and we chose treatments that could suspend AP activity after implantation. CVF is a C3b analog that forms a stable AP convertase with Bb (CVFBb), and unlike host AP C3 convertases, CVFBb is not susceptible to inhibitory activity of the complement regulators. 25 Consequently, treatment with CVF rapidly depletes circulating C3
and diminishes FB, fully exhausting complement activity. 22 We depleted AP by injecting 20 μg CVF IP into newly pregnant mice and examined Western Blots of serum for C3. This approach yielded no detectable C3 for the next 4 days, with C3 levels returning to 50% of normal by 7 days post-injection. The fetuses were genotyped and the placenta examined at 11.5 dpc. CVF treatment administered between 3.5 and 5.5 dpc rescued Crry −/− mice, compared to controls (Table 1 ).
Treatment at 6.5 or 7.5 dpc led to ~50% rescue. Of note, CVF treatment had no adverse effect on pup survival, as Crry −/− pups were born to CVF-treated mothers similar to controls (Table 2) , matured as expected,
and Crry −/− females were fertile (not shown).
| Effects of depletion of properdin by anti-properdin antibody
Properdin (P) is critical for AP activity in many systems as this positive regulator stabilizes the C3 convertase 5-to 10 fold. [26] [27] [28] The (Table 3) . 29 Treatment with a neutralizing anti-mouse properdin mAb also rescued Crry −/− concepti. 29 Specifically, treatment with 1 mg of the H4 hamster anti-mouse properdin mAb at 6.5 and 7.5 dpc resulted in 32% Crry −/− pup viability, compared to the expected 0% without treatment (P = .0005, 25 pups, 4 litters) and the 50% viability expected from Crry +/− female × Crry −/− male.
| Histology of the implantation site
The above results showed that conception loss was prevented if AP inhibition began before 6.5 dpc, and a partial effect existed if inhibition began by 6.5-7.5 dpc. TA B L E 2 Treatment with CVF enables the birth of Crry −/− pups a 5.5 dpc and are bathed in blood at 6.5 dpc. 20 The yolk sac placenta offers nutrition to the conceptus until 9.5 dpc, when the labyrinthine placenta assumes the major role in maternal-fetal exchange ( Figure 2 ). Importantly, we observed that at 8.5 dpc there was a substantial difference in the size of the allantoic vessels, a lack of proliferation of the labyrinthine trophoblasts, and smaller than control embryos in Crry −/− gestations ( Figure 3) . Moreover, the Crry −/− implantations at 9.5 dpc failed to evolve like controls, with an undeveloped labyrinth and unexpanded chorioallantoic vessels (Figure 4 ). We next treated pregnant mice at 4.5 dpc with RB6-8C5, a mAb that depletes Gr-1 (Ly-6C/G) positive cells, the majority of which are neutrophils, and we confirmed the absence of neutrophils at the sites of implantation at 7.5 dpc (Figure 6) . Examination of the surviving concepti at 10.5 and 13.5 dpc (Table 5) , along with genotyping of litters ( Table 6 ), indicated that neutrophil depletion by RB6-8C5 did not improve Crry −/− viability. Similarly, depletion of neutrophils by treatment of pregnant mice with an antiLy6G-specific Ab (1A8, 500 μg/mouse) had no detectable effect (Table 6 ). We concluded that neutrophils are not essential for loss of the Crry −/− embryos.
| Anaphylatoxin
| D ISCUSS I ON
The AP of the complement system is a constant sentinel, activating continuously on surfaces and in the fluid phase. 15, 31 Regulators on cell membranes and in plasma are essential to control the level of activation. Crry is widely expressed on the surface of mouse cells and carries cofactor activity. 32 In plasma and on cellular debris, factor H (FH) performs a similar role. Crry is able via CA to permanently stop AP activation on cell membranes. 33 In the Crry −/− mouse model, excessive AP activation leads to conceptus demise by 8.5 dpc of development, highlighting the critical role played by regulators of the AP. Crry −/− pups can be rescued by down modulating the levels of the AP activating proteins in the mother. 15 The data herein show that transient depletion of the AP, either with CVF or an anti-properdin Ab, is sufficient to rescue Crry −/− concepti. There is a critical window at 6.5-7.5 dpc when AP activation leads to conceptus loss. In the case of CVF, treatment prior to this window produces full rescue, but treatment during this 24-hour period rescues about one-half of the concepti. Interestingly, if CVF is given at 3.5 dpc prior to implantation of the blastocyst into the decidua, maternal C3 levels rise to ~50% by 7.5 dpc ( 
| Timing of C3 deposition
C3 deposition on the ectoplacental cone of the Crry −/− mouse occurs at approximately 7.5 dpc. 13, 14 We propose this takes place because there is no membrane-based complement inhibitor on these cells.
Decay-accelerating factor (DAF), a GPI-anchored regulator, is not expressed in the labyrinthine placenta until after ~10.5 dpc. 13 Other C3 regulators of complement such as FH are present in maternal blood but they are unable to compensate for Crry deficiency. For example, FH is normal in Crry −/− mouse but this complement regulator is insufficient to limit the diffuse AP activation observed on cells in the Crry −/− mouse. 15 We surmise that the underlying cause of conceptus loss in this model is a dysregulated AP of complement activation on cell membranes.
| Mechanism of loss
In the Crry −/− mouse model, conceptus lethality is the result of insufficient complement regulatory capacity. The current study was designed to identify the early events that contribute to the pathogenesis in this system. Previous work employing knockout mice showed that fetal loss requires maternal AP components FB, FD,
properdin, and C3, that is, all 4 components of the AP. Here, we
extend these studies to demonstrate that depletion of maternal AP components by 6.5 dpc, utilizing CVF treatment or neutralization of properdin with an Ab, rescues the Crry −/− embryo. Within the inherent 0.5 dpc in the Theiler staging system, the ~6.5 dpc critical time period is when extraembryonic ectoplacental cone cells become bathed in maternal blood and, consequently, immersed in maternal complement. 20 Wild-type components of the developing labyrinthine placentas connect to the maternal vasculature by 8.5 dpc (Figures 2 and 3) , and by 9.5 dpc the labyrinthine hemochorial placenta replaces the yolk sac placenta to assume the major duty of supplying nutrients to the fetus. In the Crry −/− embryo, the fusion of the allantois to the chorion during labyrinthine assembly does not occur because the chorionic plate fails to develop and the labyrinthine trophoblast does not mature to be permeated by allantoic fetal vessels (Figures 2 and 3 ).
Previous investigations of placental maldevelopment in the Crry −/− model have ruled out involvement of Ab, 14 major contributions of C4 and C6. [13] [14] [15] 19 We now show there is no role for neutrophils. Notably, maternal C5 deficiency has a limited restorative effect, suggesting a minor role for C5a. [13] [14] [15] 19 Thus, the Crry −/− model studies confirm a cause and effect relationship between complement regulatory deficiency leading to excess AP activity and aberrant placental development. Importantly, other mouse models demonstrate that placental insufficiency can occur through different complement-dependent scenarios: in the APS model, human autoantibodies bind autoantigens in the mouse placenta where they activate complement 34 while in the abortion-prone mating combination of CBA/J female × DBA/2 male complement is activated via the lectin pathway. 35 The strengths of our study include the approaches that allowed us to identify that a deficiency of maternal C3aR or a lack of neutrophils does not prevent conceptus loss. A weakness is that we can only speculate that C3 deposition begins based on when maternal 
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